triptonide has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Z; Du, L; Han, H; Zhang, B; Zhou, Q | 1 |
| Cao, Z; Chen, B; Li, Y; Meng, M; Xiang, S; Xu, X; Yang, P; Zhang, B; Zhang, T; Zhao, Z; Zhou, Q | 1 |
2 other study(ies) available for triptonide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Triptonide potently suppresses pancreatic cancer cell-mediated vasculogenic mimicry by inhibiting expression of VE-cadherin and chemokine ligand 2 genes.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Chemokine CXCL2; Drug Discovery; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Triterpenes | 2018 |
Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth.
Topics: Animals; Carcinogenesis; Enzyme Activation; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NZB; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Pancreatic Neoplasms; Random Allocation; Treatment Outcome; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |